Blood: Self-transplant or allogeneic transplantation, who should patients with external T-NHL choose?

The standard first-line therapy for young patients with extrinsic T-cell lymphoma consists of six courses of CHOP or CHOEP, which are then consolidated with high-dose therapy and auto stem cell transplantation (AutoSCT).
, Schmitz and others speculated that allogen hematopoietic stem cell transplantation (AlloSCT) could also improve the prognosis of such patients, and this Phase III randomized trial was conducted to validate it.
study recruited 104 patients aged 18-60 with weekly T-cell lymphoma with lymph nodes other than APK-ALCL, covering all stages and all IIPI-rated patients except Phase 1 and aaIPI0.
subjects were randomly grouped, receiving 4 x CHOEP and 1 x DHAP followed by high-dose therapy and AutoSCT or myelin pre-treatment and AlloSCT.
end point of the event is 3 years event-free survival (EFS).
42 months after the survival prognosis median follow-up of patients in different treatment groups, the three-year EFS for patients treated with AlloSCT was 43% (95% CI 29%-57%), compared with 38% (25%-52%) for patients treated with AutoSCT;
of the 21 patients who had alosCT relapsed, while 13 (36%) of the 36 patients who had AutoSCT relapsed.
, none of the 26 patients who performed AlloSCT (31%) and 41 patients who performed AutoSCT died of transplant-related toxicity.
cumulative (non-) relapse mortality, the survival prognosis after standard chemotherapy in young patients with T-cell lymphoma was consolidated by an autobiographic stem cell transplant or an allogeneic stem cell transplant.
effect of the transplant against lymphoma after an allogeneic transplant was offset by the transplant-related mortality rate.
cho(E) P followed autoSCT as a preferred treatment option for transplantable patients.
AlloSCT as a new option for patients who relapse after autoSCT treatment.
。